Moreover, EV hybrid treatment exhibited significant cytotoxicity against DR5‐expressing melanoma cells compared to anti‐DR5 Ab‐conjugated and ulixertinib‐loaded LNPs at a drug concentration of 2.5 μm (Figure S12c, Supporting Information). The gene discussed is TNFRSF10B; the disease is melanoma.